Market News

VLA15 is the only Lyme disease vaccine candidate currently in clinical development 

The company's goal is to design and test new vaccines for novel pathogens within 100 days of a potential pandemic threat 

Smaller companies targeting rare and extremely specific treatment areas are leading the charge in this emerging market.  

The $3.3 billion deal will strengthen GSK’s vaccine pipeline. 

The site will produce customisable bioprocess container systems. 

Samsung Biologics has full ownership over Samsung Bioepis after purchasing Biogen’s stake

The investment will expand operations over two years at facilities in Taiwan and Canada

Asahi plans to use the CDMO to propel its bioprocess business

Several mega-deals have made a splash in the pharma and life sciences industries over recent years – from AstraZeneca’s acquisition of Alexion for $39 billion to Gilead Sciences’ $21 billion purchase of Immunomedics. With am...

Drugmakers have agreed to speed up the market launch of new drugs in underserved EU member states as an alternative to stricter regulation. 

The expansion includes the addition of automated and high-speed production lines. 

Construction of Plant 4 – dubbed Super Plant – will be complete in 2023 

TraceLink’s Product Availability Intelligence will enable stakeholders to predict drug shortages months in advance  

Germany forms more than half of the EU’s medical cannabis market  

Sanofi will reduce its stake in EUROAPI to 30% after listing 

Symbiosis, Freeline Therapeutics and Cell and Gene Therapy Catapult joined forces to decrease drug manufacturing timelines

The German healthcare group says the acquisitions will accelerate strategic growth in biopharmaceuticals and MedTech 

International pharma companies may do well to consider setting up shop in the Netherlands, according to data compiled by Mercator by Citco

The expansion will provide additional cold storage and visual inspection capacity, as well as cleanrooms for device assembly and secondary packaging

The expansion will take two years and add 180 new jobs. 

Many clinical trials have been put on hold or cancelled due to the war in Ukraine 

Market set to grow as companies face fewer operational restrictions and COVID-19 drug development continues at pace

Bristol Myers Squibb to leverage Volastra’s CINtech platform to discover and develop oncology drug candidates.  

A redeveloped R&D facility will enhance Seqens' capabilities in developing and producing APIs and active delivery systems development

The CDMO will produce drug substance for clinical supply at its HPAPI manufacturing site in Nansha, China

KKR closes its previously-announced acquisition of Biosynth Carbosynth and announces Biosynth's acquisition of vivitide. 

The CDMO has expanded its ultra-low temperature commercial packaging, labelling and distribution solutions facility in Ireland

The largest sums of capital were awarded to US biotech companies, followed by companies based in Mainland China and the UK

The development and cGMP manufacturing laboratories will provide additional early-phase HPAPI manufacturing capabilities

The Taiwan-based nebuliser specialist has signed an MoU with Formosa Laboratories, and Formosa Pharmaceuticals to form a biopharma one-stop-shop

Public funding of more than €7 million will help the project to find a solution to prohibitive production costs of developing stem cell-based therapies

By joining forces, the two companies will be able to bring Dispersome to the market faster for novel drug development

The two transactions enable Recipharm to expand its ATMP offering into virotherapies and boost its US biologics services

MediCane Health's EU-GMP certification helps to bridge the pharma-cannabis gap

A diverse range of sectors and industries come together in partnership to address infection management, advocating a whole system approach

The investment covers two expansions to accommodate several pipeline products moving to commercial scale

The $1.5 billion investment will fund a parenteral manufacturing facility in North Carolina and a biopharmaceutical manufacturing site in Ireland

Initial Public Offerings totalled £1,304 million, an increase of 434% from 2020, but more needs to be done to connect the UK's life sciences and finance sectors

Xpress Pharmaceutics will facilitate adaptive clinical trials and reduce the time taken to complete FIH studies

The collaboration includes a multimillion-dollar investment to expand glass technology that will advance packaging and delivery systems

The latest coronavirus updates and developments impacting the global pharmaceutical supply chain

The agreement will enable millions of patients in more than 100 low- and middle-income countries to gain access to molnupiravir

Last year the company reduced its electricity requirements by 40%

Astrea Pharma will be the new owner of the facility at Fontaine-lès-Dijon

The CDMO will provide expertise and capacity to advance BravoBio's vaccine pipeline

The move is expected to bring added value to customers by coupling biology services with existing chemistry capabilities

This second facility gives the company a significant power multiplier for export capacity and geographical reach

We are approaching the end of a year which saw global vaccine rollout for COVID-19, 44 novel drug approvals (to date) and the return of the CPHI Worldwide in-person event.

Transaction adds new technologies and capabilities in large molecules, including vaccines and gene therapy, to its global offering

New campus will support the company as it approaches potential commercialisation of its rapidly progressing clinical candidates

CDMO currently manufacturing LAAB combination treatment  and will start on cancer immunotherapy product from next year

Merck will design the manufacturing process to help accelerate self-sufficient vaccine development and manufacturing in West Africa

The new agreement extends to 2028 and allows Oxord Biomedica to work with other potential partners across all CAR-T targets

The dedicated pharma trade lane will unite key compliant and sector-certified supply chain stakeholders and help Abu Dhabi to strengthen its capabilities as a life sciences hub

The new facility will focus on the research of excipients for oral dosage forms, drug delivery systems, nutraceutical APIs and innovative pharma ingredients

CPHI has launched its forward-looking pharma trend report for 2022 and it is now available to read on CPHI Online.

A 30,000-sq. ft cGMP facility and a separate R&D site will work alongside each other to provide end-to end product development solutions for Singapore and low- and middle-income countries

The facility will be the first to use Evolve’s innovative PlasmaCap EBA technology to produce plasma-derived therapeutics

The combined company intends to lead in the space of oral formulations, solving customers' complex formulation challenges

It could take pharmaceutical companies months to tweak their COVID-19 vaccines to provide sufficient protection against the Omicron variant of the coronavirus if it poses a risk of serious illness.

The new route uses a novel enzyme, cytidine aminotransferase, which would reduce the manufacturing cost of the drug

The offering will accelerate timelines for the development and manufacturing of molecules and disruptive technologies

The expansion is expected to make the company the largest CDMO in oligonucleotide production in 2025

The new 31,000-sq. ft building will bring additional commercial spray drying capacity for customers who favour US-based manufacturing

The transaction expands ANI’s R&D pipeline and adds nine new customers to its growing CDMO business

The facility's total 60,000-L capacity supports growing demand for manufacture of late-phase and commercial projects

China is the pharma industry’s biggest gainer in the 2021 CPHI Annual Rankings, with digital matchmaking driving new waves of partnerships

The state-of-the-art centre will be built in Prince Edward Island to support domestic biomanufacturing capabilities

The expansion includes the installation of a pilot suite with a 50-L fermenter and automation upgrades to accelerate clinical and commercial projects

SK's financial backing enables CBM to address significant capacity constraints in the cell and gene therapy manufacturing space

The proposed state-of-the-art facility could potentially produce up to 100 million vaccine doses each year for Australians

WuXi will use its new modality platform to provide an end-to-end solution for oligonucleotide peptide

The CDMO will raise its headcount to 8,000 across its 19 global facilities amid increased demand for services

The $20.1 million investment will enable the company to manufacture pharma products for the Adcock Ingram Group and for other clients

The transaction will support Cannabics' planned IND fillings and Phase I/II (a) clinical trials

The first-of-its-kind centre will offer biopharma clients convenience and efficiencies in the rapidly expanding Northeast

The increasing outsourcing trend among pharmaceutical companies represents a promising opportunity for CDMOs. This panel discussion at CPHI Worldwide touched upon some of the opportunities, hurdles, and trends ahead for the CDMO market

Expected increase in approvals for gene therapies, gene-modified cell therapies and recombinant vector vaccines will also increase pressure on manufacturers to build new capacity

The CDMO says the suite will help to "bring back manufacturing to the US"

The companies will establish a Centre of Excellence focused on exosome manufacturing and characterization technologies

The concept of patient centricity has many nuances, and designing dosage forms needs to be underpinned by a multi-functional perspective utilised as early as possible, say experts

Clients to receive accelerated quality testing and reduced turnaround times

Rather than looking back at what has been a challenging past few months, this Trend Report - featuring highlights from the Pharmapack 2021 content programme - has been written very much in the spirit of looking forward and addressing the key challenges...

Rise of innovative companies with high-risk portfolios will necessitate need for CDMOs, says Thermo Fisher senior executive

By completion at the end of 2022, the campus will accommodate 18 cGMP viral vector manufacturing suites

COVID-19 pandemic has exposed weaknesses and sector faces new challenges driven by rising costs of production in China

Current EU regulatory systems too overwhelmed by paper, head of European association representing generics, biosimilars and value added medicines industries tells CPHI Worldwide online conference

Country expected to grow threefold over the next decade due to increased focus on complex generics, biosimilars and specialty products

One site will focus on microbial production, the other on small-scale mammalian-based production

The CDMO will supply expertise in GMP sterile fill-finish manufacturing and controlled-substances

As a network member, the company hopes to help reduce the US's reliance on overseas imports by providing domestic API capability

According to unnamed sources in Politico report, company’s vaccine batches have not met FDA purity level standards

UCB Pharma is informed by agency that action on application for psoriasis treatment is being deferred until on-site visits can be made

Together the companies will attempt to overcome "black box" challenges to enable more robust and consistent results for clients

The move, coupled with the plants's passing of a pharmaceutical GMP compliance inspection, will enable company to accelerate the R&D of its novel Advanced TCMPs

The biologics CDMO says it expects its new 53,000-sq.ft facility will be operational within 18 months

Manufacturer starts development of API for molnupiravir, which is set to become world’s first oral treatment against coronavirus

Panel discusses how healthcare institutions are adapting to calls for more sustainability in various processes in the value chain

The transaction expands the CDMO's GMP biopharmaceutical and vaccine manufacturing capabilities

The new the 140,000-sq. ft facility will support commercialisation and industrialisation of viral vectors

Having acquired a 53,000 sq-ft property in Berlin, the company plans to set up new laboratories, production and cleanrooms

Pre-filled syringes (PFS) could help immensely in solving the challenges of rolling out future mass vaccination campaigns, according to experts at Becton Dickinson (BD).

The LSCC provides an additional 30% in mammalian large-scale capacity for the company's own pipeline and for third parties

Just as 'food miles' have become a key concern among consumers in recent years, patients now want to know more about 'medicine miles', study commissioned by Teva finds

Electronic devices and connectivity are being progressively included in drug delivery devices, bringing positive outcomes to all stakeholders, according to drug device combinations specialist, Nemera Tuesday

The 1.5 million-sq. ft Switzerland-based facility is part of the company's strategic partnership with CSL Limited

By providing AAV process development, scale up and cGMP manufacturing services, Forge hopes to bolster Solid's gene therapy pipeline

The transaction will generate $102.25 million to support the company's product pipeline and scaling up commercial activities for Afrezza

The facility will increase the production capacity of cell culture media products and provide a hub for European and global markets

The company plans to open a new 130,000-sq. ft plant in Ann Arbor in late 2023

The acquisition will add 13 approved products and additional pipeline products

Only 0.3% of the 5.76 billion doses administered worldwide have been distributed to low-income countries

The private investment firm plans to acquire SEQENS and merge it with Wavelength Pharmaceuticals

The agreement will contribute toward the equivalent reduction of 937,426 tons of carbon dioxide emissions

As a safe, effective and convenient way to administer injectable medications, pre-filled syringes (PFS) have become the injection system of choice for a growing number of drugs. PFS allow healthcare professionals to easily handle syringes, reduce waste...

The company's new Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline transition from research to clinical environments

The CDMO will provide commercial manufacturing and packaging services for Phathom's novel, orally active P-CAB

The transaction is expected to accelerate Catalent's growth in global softgel and oral dose formulation and manufacturing services

The expansion is anticipated to speed up development and time-to-market of novel treatments and vaccines for COVID‑19

The expansion plans include an additional manufacturing line, a new cleanroom and a new process development lab